Overview

Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of this clinical trial is to evaluate the effectiveness and safety of oncolytic viruses H101 intra-tumor injection combined with or without radiotherapy in refractory or recurrent gynecological malignancies. And further research the mechanism of oncolytic viruses H101.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Liu Zi
Criteria
Inclusion Criteria:

- Written informed consent obtained.

- Age ≥ 18 years at the time of study entry.

- Histological or Cytologically diagnosed gynecological malignancies.

- Failure to prior standard treatment (surgery, chemotherapy, radiotherapy);

- Refractory/recurrence/metastasis gynecological cancer

- At least one measurable lesion according to the RECIST1.1.

- Cooperative Oncology Group-Status (ECOG Status) 0-3.

- The last treatment should be over 2 weeks.

Exclusion Criteria:

- History or evidence of active autoimmune disease that requires systemic treatment.

- Participated in other anti-tumor clinical trials within 4 weeks.

- Patients who have a contraindication to similar drugs.

- That failure to follow up regularly.